UroGen Pharma (URGN) Short Interest Ratio & Short Volume → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free URGN Stock Alerts $13.21 -0.57 (-4.14%) (As of 05/16/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability UroGen Pharma Short Interest DataCurrent Short Volume4,430,000 sharesPrevious Short Volume4,200,000 sharesChange Vs. Previous Month+5.48%Dollar Volume Sold Short$61.22 millionShort Interest Ratio / Days to Cover12.7Last Record DateApril 30, 2024Outstanding Shares23,450,000 sharesPercentage of Shares Shorted18.89%Today's Trading Volume207,409 sharesAverage Trading Volume331,386 sharesToday's Volume Vs. Average63% Short Selling UroGen Pharma ? Sign up to receive the latest short interest report for UroGen Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatURGN Short Interest Over TimeURGN Days to Cover Over TimeURGN Percentage of Float Shorted Over Time Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. UroGen Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20244,430,000 shares $61.22 million +5.5%N/A12.7 $13.82 4/15/20244,200,000 shares $63.42 million +0.2%N/A11.5 $15.10 3/31/20244,190,000 shares $62.85 million -1.4%N/A12.6 $15.00 3/15/20244,250,000 shares $61.46 million +8.1%N/A12.4 $14.46 2/29/20243,930,000 shares $72.04 million -2.0%N/A12.7 $18.33 2/15/20244,010,000 shares $75.39 million +23.0%N/A13.2 $18.80 Get the Latest News and Ratings for URGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. 1/31/20243,260,000 shares $51.18 million -3.8%N/A11 $15.70 1/15/20243,390,000 shares $49.46 million -4.5%N/A12.9 $14.59 12/31/20233,550,000 shares $53.25 million +15.6%N/A13.5 $15.00 12/15/20233,070,000 shares $46.05 million +5.1%N/A11.3 $15.00 11/30/20232,920,000 shares $38.51 million +3.2%N/A12.4 $13.19 11/15/20232,830,000 shares $32.77 million +23.6%N/A11.4 $11.58 10/31/20232,290,000 shares $25.67 million +39.6%N/A7.9 $11.21 10/15/20231,640,000 shares $21.48 million +14.7%N/A2.6 $13.10 9/30/20231,430,000 shares $20.03 million +10.9%N/A2.3 $14.01 9/15/20231,290,000 shares $20.52 million -8.5%N/A2.1 $15.91 8/31/20231,410,000 shares $24.65 million -15.1%N/A2.2 $17.48 8/15/20231,660,000 shares $37.12 million +5.7%N/A2.7 $22.36 7/31/20231,570,000 shares $34.01 million +55.5%N/A2.8 $21.66 7/15/20231,010,000 shares $9.28 million +11.1%5.1%4 $9.19 6/30/2023909,100 shares $9.41 million +38.5%4.6%3.8 $10.35 6/15/2023656,300 shares $8.07 million -23.0%3.3%2.7 $12.29 5/31/2023852,100 shares $8.44 million -9.8%4.3%4.6 $9.90 5/15/2023944,700 shares $11.16 million +29.3%4.8%5.4 $11.81 4/30/2023730,500 shares $8.47 million -1.8%3.7%4.3 $11.59 4/15/2023743,700 shares $7.16 million +16.3%3.8%5.8 $9.63 3/31/2023639,500 shares $5.91 million +2.3%3.3%5.6 $9.24 3/15/2023625,300 shares $6.02 million +5.5%3.3%6.3 $9.63 2/28/2023592,900 shares $6.11 million +2.8%3.1%6.7 $10.30 2/15/2023576,700 shares $5.29 million +1.2%3.0%6.4 $9.17 1/31/2023569,700 shares $5.92 million +0.0%3.0%6.6 $10.39 1/15/2023569,600 shares $4.88 million -15.2%2.9%7.7 $8.56 12/30/2022671,700 shares $5.96 million -0.2%3.5%8.9 $8.87 12/15/2022673,000 shares $5.32 million +0.1%3.5%10.2 $7.91 11/30/2022672,600 shares $5.76 million -1.0%3.5%10.3 $8.57 11/15/2022679,700 shares $6.17 million -9.5%3.5%10.5 $9.08 10/31/2022751,100 shares $8.90 million -31.7%3.9%13 $11.85 10/15/20221,100,000 shares $12.65 million -20.3%5.8%19.5 $11.50 9/30/20221,380,000 shares $11.48 million -3.5%7.2%25.6 $8.32 9/15/20221,430,000 shares $13.46 million +1.4%7.5%15 $9.41“Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. URGN Short Interest - Frequently Asked Questions What is UroGen Pharma's current short interest? Short interest is the volume of UroGen Pharma shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 4,430,000 shares of URGN short. Learn More on UroGen Pharma's current short interest. What is a good short interest ratio for UroGen Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. URGN shares currently have a short interest ratio of 13.0. Learn More on UroGen Pharma's short interest ratio. Is UroGen Pharma's short interest increasing or decreasing? UroGen Pharma saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 4,430,000 shares, an increase of 5.5% from the previous total of 4,200,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does UroGen Pharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to UroGen Pharma: Vanda Pharmaceuticals Inc. (4.17%), XOMA Co. (2.33%), 23andMe Holding Co. (12.81%), Nature's Sunshine Products, Inc. (0.50%), Ventyx Biosciences, Inc. (14.79%), CorMedix Inc. (17.94%), Rani Therapeutics Holdings, Inc. (10.88%), Aquestive Therapeutics, Inc. (5.79%), Mersana Therapeutics, Inc. (8.92%), Atai Life Sciences (5.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short UroGen Pharma stock? Short selling URGN is an investing strategy that aims to generate trading profit from UroGen Pharma as its price is falling. URGN shares are trading down $0.57 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against UroGen Pharma? A short squeeze for UroGen Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of URGN, which in turn drives the price of the stock up even further. How often is UroGen Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including URGN, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Vanda Pharmaceuticals Short Interest Data XOMA Short Interest Data 23andMe Short Interest Data Nature's Sunshine Products Short Interest Data Ventyx Biosciences Short Interest Data CorMedix Short Interest Data Rani Therapeutics Short Interest Data Aquestive Therapeutics Short Interest Data Mersana Therapeutics Short Interest Data Atai Life Sciences Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:URGN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressHow Biden has already won 2024Porter & Company